S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
Log in

Amedisys Stock Forecast, Price & News

+10.64 (+3.51 %)
(As of 01/22/2021 12:00 AM ET)
Today's Range
Now: $313.54
50-Day Range
MA: $286.58
52-Week Range
Now: $313.54
Volume212,178 shs
Average Volume181,481 shs
Market Capitalization$10.29 billion
P/E Ratio62.83
Dividend YieldN/A
Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. The Hospice segment offers services that is designed to provide comfort and support for those who are dealing with a terminal illness, including heart disease, pulmonary disease, Alzheimer's, or cancer. The Personal Care segment provides assistance for patients with the activities of daily living. As of February 18, 2020, the company owned and operated 479 care centers in 38 states and the District of Columbia. Amedisys, Inc. was founded in 1982 and is headquartered in Baton Rouge, Louisiana.
Amedisys logo


Overall MarketRank

1.17 out of 5 stars

Medical Sector

848th out of 1,922 stocks

Home Health Care Services Industry

6th out of 9 stocks

Analyst Opinion: 1.4Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Home health care services
Sub-IndustryHealth Care Services
Current SymbolNASDAQ:AMED



Sales & Book Value

Annual Sales$1.96 billion
Cash Flow$6.63 per share
Book Value$19.89 per share


Net Income$126.83 million


Market Cap$10.29 billion
Next Earnings Date2/16/2021 (Estimated)
+10.64 (+3.51 %)
(As of 01/22/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AMED News and Ratings via Email

Sign-up to receive the latest news and ratings for AMED and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Amedisys (NASDAQ:AMED) Frequently Asked Questions

How has Amedisys' stock been impacted by COVID-19?

Amedisys' stock was trading at $170.47 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, AMED stock has increased by 83.9% and is now trading at $313.54.
View which stocks have been most impacted by COVID-19

Is Amedisys a buy right now?

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amedisys in the last year. There are currently 3 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Amedisys stock.
View analyst ratings for Amedisys
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Amedisys?

Wall Street analysts have given Amedisys a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Amedisys wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Paul B. Kusserow's approval rating as Amedisys' CEO?

297 employees have rated Amedisys CEO Paul B. Kusserow on Glassdoor.com. Paul B. Kusserow has an approval rating of 79% among Amedisys' employees.

When is Amedisys' next earnings date?

Amedisys is scheduled to release its next quarterly earnings announcement on Tuesday, February 16th 2021.
View our earnings forecast for Amedisys

How were Amedisys' earnings last quarter?

Amedisys, Inc. (NASDAQ:AMED) released its earnings results on Monday, November, 2nd. The health services provider reported $1.52 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $1.27 by $0.25. The health services provider had revenue of $544.07 million for the quarter, compared to analyst estimates of $533.09 million. Amedisys had a net margin of 8.22% and a trailing twelve-month return on equity of 26.41%.
View Amedisys' earnings history

What guidance has Amedisys issued on next quarter's earnings?

Amedisys issued an update on its FY20 earnings guidance on Wednesday, October, 28th. The company provided EPS guidance of $6.02-6.08 for the period, compared to the Thomson Reuters consensus estimate of $4.95. The company issued revenue guidance of $2.067-2.072 billion, compared to the consensus revenue estimate of $2.06 billion.

What price target have analysts set for AMED?

12 brokers have issued twelve-month price targets for Amedisys' shares. Their forecasts range from $190.00 to $325.00. On average, they anticipate Amedisys' share price to reach $263.69 in the next year. This suggests that the stock has a possible downside of 15.9%.
View analysts' price targets for Amedisys
or view Wall Street analyst' top-rated stocks.

Are investors shorting Amedisys?

Amedisys saw a increase in short interest in December. As of December 31st, there was short interest totaling 534,100 shares, an increase of 40.4% from the December 15th total of 380,500 shares. Based on an average trading volume of 161,800 shares, the short-interest ratio is currently 3.3 days.
View Amedisys' Short Interest

Who are some of Amedisys' key competitors?

What other stocks do shareholders of Amedisys own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amedisys investors own include NVIDIA (NVDA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Pfizer (PFE), Adobe (ADBE), Intel (INTC), QUALCOMM (QCOM), Broadcom (AVGO), Cisco Systems (CSCO) and The Home Depot (HD).

Who are Amedisys' key executives?

Amedisys' management team includes the following people:
  • Mr. Paul Berthold Kusserow, Chairman, Pres & CEO (Age 60, Pay $1.33M)
  • Mr. Scott G. Ginn, Chief Financial Officer (Age 52, Pay $1.22M)
  • Mr. Christopher T. Gerard, Chief Operating Officer (Age 54, Pay $1.34M)
  • Mr. David L. Kemmerly, Chief Legal & Gov. Affairs Officer (Age 58, Pay $851.77k)
  • Ms. Sharon Brunecz, Chief HR Officer (Age 54, Pay $844.58k)
  • Mr. Pete Hartley, CTO & Sr. VP of Bus. Operations Systems
  • Mr. Michael P. North, Chief Information Officer (Age 56)
  • Mr. Denise Bohnert, Chief Compliance Officer (Age 43)
  • Kendra Kimmons, VP of Marketing & Communications
  • Mr. John Nugent, Chief Acquisitions Officer

What is Amedisys' stock symbol?

Amedisys trades on the NASDAQ under the ticker symbol "AMED."

Who are Amedisys' major shareholders?

Amedisys' stock is owned by many different retail and institutional investors. Top institutional investors include Riverbridge Partners LLC (2.25%), British Airways Pensions Investment Management Ltd (0.17%), Columbus Circle Investors (0.07%), Gradient Investments LLC (0.06%), Louisiana State Employees Retirement System (0.02%) and Sabal Trust CO (0.02%). Company insiders that own Amedisys stock include Bruce D Perkins, Christopher Gerard, David B Pearce, David L Kemmerly, Denise M Bohnert, Donald A Washburn, Jake L Netterville, Jeffrey A Rideout, Julie D Klapstein, Michael Paul North, Scott G Ginn, Sharon Brunecz, Teresa L Kline and Vickie L Capps.
View institutional ownership trends for Amedisys

Which major investors are selling Amedisys stock?

AMED stock was sold by a variety of institutional investors in the last quarter, including Columbus Circle Investors, Pacer Advisors Inc., British Airways Pensions Investment Management Ltd, Vivid Financial Management Inc., Gradient Investments LLC, We Are One Seven LLC, State of Alaska Department of Revenue, and Contravisory Investment Management Inc.. Company insiders that have sold Amedisys company stock in the last year include Christopher Gerard, David L Kemmerly, Denise M Bohnert, Julie D Klapstein, Michael Paul North, Scott G Ginn, and Sharon Brunecz.
View insider buying and selling activity for Amedisys
or view top insider-selling stocks.

Which major investors are buying Amedisys stock?

AMED stock was acquired by a variety of institutional investors in the last quarter, including Riverbridge Partners LLC, Kestra Advisory Services LLC, HBW Advisory Services LLC, Arthur M. Cohen & Associates LLC, 6 Meridian, Crossmark Global Holdings Inc., Park Avenue Securities LLC, and Kinloch Capital LLC. Company insiders that have bought Amedisys stock in the last two years include Bruce D Perkins, Teresa L Kline, and Vickie L Capps.
View insider buying and selling activity for Amedisys
or or view top insider-buying stocks.

How do I buy shares of Amedisys?

Shares of AMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Amedisys' stock price today?

One share of AMED stock can currently be purchased for approximately $313.54.

How big of a company is Amedisys?

Amedisys has a market capitalization of $10.29 billion and generates $1.96 billion in revenue each year. The health services provider earns $126.83 million in net income (profit) each year or $4.40 on an earnings per share basis. Amedisys employs 21,300 workers across the globe.

What is Amedisys' official website?

The official website for Amedisys is www.amedisys.com.

How can I contact Amedisys?

Amedisys' mailing address is 3854 AMERICAN WAY SUITE A, BATON ROUGE LA, 70816. The health services provider can be reached via phone at 225-292-2031 or via email at [email protected]

This page was last updated on 1/23/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.